Novacta secures funding to further develop antibiotics

07/9/2009 | Business Weekly (U.K.)

Novacta Biosystems secured more than $21 million in a financing round led by Celtic Pharma's second fund. The company will use the funding to advance the development of its line of hospital superbug-focused antibiotics, called "lantibiotics." Drugs being developed include treatments for Clostridium difficile and methicillin-resistant Staphylococcus aureus.

View Full Article in:

Business Weekly (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID